Mazindol in the Treatment of Parkinson's Disease
- 1 December 1983
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 40 (13) , 788-790
- https://doi.org/10.1001/archneur.1983.04050120038004
Abstract
• Mazindol, a drug that blocks the reuptake of dopamine, was studied in the treatment of Parkinson's disease in both a pilot study (12 patients) and a controlled trial (11 patients). The patients had stage II or III disease, according to the classification of Hoehn and Yahr. Both studies showed that mazindol possessed antiparkinsonian properties and that the improvement was statistically significant. The therapeutic effect was moderate, but could be of value for patients in the early stages of the disease. The drug was well tolerated; only two patients had side effects.This publication has 6 references indexed in Scilit:
- Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 1979
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977
- Treatment of Parkinson's Disease with BromocriptineNew England Journal of Medicine, 1976
- A Non-Amphetamine Anorectic Agent: Preclinical Background and a Double-Blind Clinical TrialJournal of International Medical Research, 1975
- ParkinsonismNeurology, 1967
- Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen SystemsJournal of Molecular Medicine, 1960